A child, 2 years with the 'hypercalprotectinaemia with hyperzincaemia' clinical syndrome, presented with atypical symptoms and signs, notably persistent fever of approximately 388C, thrombocythaemia of > 700 3 10 9 /l and a predominance of persistent intestinal symptoms. In an effort to find a cure by identifying the dysregulated pathways we analysed whole-genome mRNA expression by the Affymetrix HG U133 Plus 2Á0 array in blood on three occasions 3-5 months apart. Major up-regulation was demonstrated for the Janus kinase/signal transducer and activators of transcription (JAK/ STAT) pathway including, in particular, CD177, S100A8, S100A9 and S100A12, accounting for the thrombocytosis; a large number of interleukins, their receptors and activators, accounting for the febrile apathic state; and the high mobility group box 1 (HMBG1) gene, possibly accounting for part of the intestinal symptoms. These results show that gene expression array technology may assist the clinician in the diagnostic work-up of individual patients with suspected syndromal states of unknown origin, and the expression data can guide the selection of optimal treatment directed at the identified target pathways.
Introduction
In 2002, a new clinical syndrome, called hyperzincaemia with hypercalprotecinaemia (Hz/Hc), was described in five patients [1, 2] , and subsequently a few additional cases were published [3] [4] [5] [6] . The syndrome has been described as a systemic inflammatory disorder without any known microbial aetiology and is linked to a pronounced (fivefold or more) systemic hyperzincaemia, and plasma levels of calprotectin increased up to two orders of magnitude over normal levels or more. Holzinger et al. [7] found recently that a few welldefined mutations in the proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) gene can cause Hz/Hz. The first case in Sweden, described by us [6] , was atypical in that gastrointestinal bleeding and diarrhoea were presenting symptoms and continued to be major clinical problems, in addition to pronounced growth retardation and persistent pronounced thrombocytosis. Despite the hyperzincaemia in serum there were no signs of zinc overload in tissues [8] .
The aetiology of the aseptic, spontaneous, intensely febrile autoinflammatory disorder in our patient remained unknown, as analyses of the PSTPIP1 and Janus kinase 2 (JAK2) genes proved to be normal. A prerequisite to finding a cure is a better understanding of the mechanisms involved, in particular to identify which signalling pathways are dysregulated. As calprotectin, the hallmark biomarker of the syndrome, is a neutrophilic granulocyte protein and our patient in addition had a persistent thrombocytosis (524-1470 3 10 because of bloody diarrhoea and stunted growth. The girl was initially breastfed, but with a slow weight gain (she followed the third centile for weight and height). In February 2008 her stools became frequent and bloody and she had a high C-reactive protein (CRP) (177 mg/l) and persistent fever ($388C). She had constantly elevated platelet counts (>700 3 10 9 /l), but granulocyte counts were normal. Haemoglobin (Hb) levels were low ($82 g/l), with no laboratory evidence of haemolysis. Additionally, thalassaemias were ruled out by chromatography of Hb (Tosoh G7; Tosoh Bioscience Inc., South San Francisco, CA, USA), blood analysis and DNA testing [9] . Details of the clinical presentation have been published previously [6, 8] . Briefly, based on very high values of zinc (89 mmol/l) in serum and calprotectin in both serum and faeces (4200 mg/l and 2175 mg/g), and all microbiological tests proving to be negative, a clinical syndrome diagnosis of hypercalprotectinaemia with hyperzincaemia was made [1] . Treatment of the intensive inflammation and febrile state was called for; the various regimens tried are summarized in Table 1 . None had any effect lasting for more than 2-5 days until fever and symptoms resumed, and the patient died in June 2011. The present laboratory studies were undertaken in an effort to identify more precisely which targets should be focused upon in future treatment efforts in this syndrome. The mother of the child gave informed consent to the publishing of the case reports. The Regional Ethics Review Board in Uppsala approved the study.
Sample collection and preparation
Whole venous blood was drawn into a PAXgene TM tube (Becton Dickinson/BD, Franklin Lakes, NJ, USA) on three different occasions, at ages 9, 14 and 17 months (Table 1) . Two healthy girls aged 4 years served as controls (sampled only once). Tubes were stored in 2808C until extraction. Total RNA was extracted from whole blood using PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland), according to the manufacturer's instructions. The extraction procedure was automated using Qiacube (Qiagen, Hilden, Germany). RNA concentration was measured with NanoDrop, ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and the RNA quality was assessed by an Agilent Bioanalyzer 2000 instrument with a eukaryote total RNA Nano chip (Agilent Technologies, Waldbronn, Germany).
Microarray chip and analysis
The chip used in this study is a whole human genome expression array (Affymetrix Inc., Santa Clara, CA, USA; array: HG U133 Plus 2Á0) that covers the whole human genome. The array contains more than 47 000 transcripts from ca. 38 000 human genes and pseudogenes; in addition to this, the chip also includes hybridization controls, poly-A controls, normalization control set and housekeeping genes. Each probe set consists of 11 probe pairs (one perfect match and one mismatch). A probe set is defined as a 869  710  815  1034  1362  1041  758  204-465  P-CRP, mg/l  177  96  54  99  112  97  81  < 4Á0  P-albumin, g/l  31  31  41  23  32  28  21  36-48 (18-40 years -89  105  58  82  85  11-17  S-calprotectin, mg/l  ---3800  1425  2500  2692  < 50  F-calprotectin mg/kg  -2175  4175  -2625  --< 50  Wb-SR, mm/h  -48  -94  ---< 21  P-calcium mmol/l  2Á41  2Á47  2Á23  2Á48  2Á34  2Á25  2Á51  2Á10-2Á55  Treatment  None  B  P  P, S, Scanner 3000 and image analysis was performed. Scanned arrays were analysed in Affymetrix GeneChip Operating Software (GCOS) version 1Á4 using global scaling to target Signal 100. All fold change (FC) values reported in the tables have a P-value < 0Á05 that we regarded as statistically significant.
Gene ontology [10] associations were used for the functional analysis of the differentially regulated genes. The observed number of genes associated with a gene ontology term was compared to the random expected number using Fisher's exact test. The test generates a probability of a random enrichment, and was performed for each term in the three gene ontology branches: biological processes, cellular components and molecular function.
JAK2 and PSTPIP1 genotyping
Genotyping of JAK2 (V617F) was performed with pyrosequencing technique at our local routine laboratory. The sequencing of the exons and the (CCTG)n repeat in the 5 0 UTR of the PSTPIP1 gene was performed by CeGaT GmbH (T€ ubingen, Germany), and of the familial Mediterranean fever gene mutation (MEFV) gene by the Department of Immunology, University of M€ unster, Germany.
Quantitative polymerase chain reaction (qPCR) validation of HIV-1 Tat specific factor 1 pseudogene 2 (HTATSF1P2) cDNA was synthesized from 500 ng total RNA (extracted as described previously) using Superscript III First-Strand Synthesis SuperMix for qPCR (Invitrogen, Carlsbad, CA, USA). qPCR was performed with 25 ng cDNA per reaction on an Applied Biosystem (ABI) 7900HT machine, and analysed with SDS version 2Á3 software. Primers and probes were Taqman Gene Expression Assays; for HTATSF1P2 (Hs02759571_s1, ABI) and for 18S rRNA (Hs99999901_s1, ABI), with 6-carboxyfluoroscein (5'-Fam) and nonfluorescent quencher (3'-NFQ) as fluorophore and quencher, respectively. The PCR was run in PCR Gene Expression Master Mix (ABI, Foster City, CA, USA) at 508C for 2 min at 958C for 10 min and 40 cycles at 958C for 15 s for denaturing and 608C for 1 min for the annealing and elongation steps. The expression of HTATSF1P2 was normalized to the expression of 18S rRNA.
Gene expression analysis of the HTATSF1P2 gene was also carried out in a number of different tissues (other than the patient investigated) to determine its normal levels. All tissues and whole blood samples were from anonymous donors; research material or cell lines, mRNA from normal placental tissue, intestine tissue, kidney tissue and bone marrow mRNAs were a kind gift from Dr Hilja Strid. Normal ovarian tissue mRNA was donated from a deceased patient at the Department of Laboratory Medicine, Section of Pathology, € Orebro University Hospital. Two variants of a promyelocytic leukaemia cell-line (HL60) resistant to a 0Á5 and 5 mM dosage of doxorubicin (HL60R0Á5 resp. HOL60R5) were a kind gift from Malin Prenkert PhD. CFBE (bronchial epithelial cell line) and CF16BE (cystic fibrosis cell line) were a kind gift from Professor Gottfried Roomans. Whole blood with normal white blood cell (WBC) count or with leucocytosis was also taken from anonymized patients sent to the routine laboratory for blood counts, in which gene expression analysis was carried out as described above.
Bioinformatic analysis of the HTATSF1P2 gene
The coding sequence region of the gene HTATSF1P2 (probe set ID 15588882_at in the present chip) was obtained from NCBI (accessed 12 May 2010). Open reading frame (ORF) analysis, homology search and sequence similarity search were performed with software available at the NCBI website (http://www.ncbi.nlm.nih.gov/). A transcription factor site search was performed with GPMine. The molecular weight and pI of the putative protein was attained from free software tools available at Expasy (http://expasy.org/). The amino acid sequence of the putative protein was analysed for hydrophobicity, motifs and domains with tools from Expasy. The prediction of the cellular localization was performed with PSORTII (http://psort.ims.u-tokyo.ac.jp/).
Results
The basic inflammatory and haematological biomarkers over time are shown in Table 1 . The most striking deviation from the normal in biomarkers, apart from the high plasma levels of orosomucoid and haptoglobin, was a pronounced thrombocytosis. Both immunoglobulin levels and WBC counts were normal over time, despite the prolonged inflammatory activity and the more than 70-fold increased serum calprotectin (a marker of neutrophil activity).
The treatments given are also shown in Table 1 . There was little effect on inflammatory biomarkers, and no lasting clinical improvement, of the five first regimens tried.
After initiation of Kinaret treatment [interleukin (IL)-1a
and 21b inhibitor, Anakinra V R ; Biovitrum AB, Stockholm, Sweden], the girl responded favourably with better contact, responding to contact with a smile, etc., but this effect also proved to be transient. Apheresis treatment was tried, with substantial initial effects on plasma levels of calprotectin and S-Zn, but within a few days after treatment the values had reverted to the initial high levels ( Table 2) .
We performed genomewide mRNA gene expression analysis patterns in peripheral blood at ages 9, 14 and 17 months. The array expression data were analysed by both inductive and deductive strategies. In the inductive (unguided) strategy, we identified the most up-or downregulated genes without any preconceived notion about which genes would be of pathophysiological interest. In the deductive (hypothesis-driven) strategy, we searched the expression data for predetermined sets of genes which define certain well-known mechanistic pathways in the inflammatory response, its regulation and its intracellular signalling pathways that were deemed as possible fits with the signs and symptoms of our patient.
Inductive strategy
The most highly up-and down-regulated genes are displayed in Table 3 . As seen, one gene is highly up-regulated at all three sampling occasions, CD177. Established pathways involving CD177 were therefore explored further using a deductive strategy.
In addition, an unannotated Affymetrix chip probe coded 15588882_at was expressed highly at the first sampling occasion, which was annotated more recently to the gene HTATSF1P2. Little is known about this gene, except that it has been reported [11] to show sequence homologies to another gene of which there is also only very scant information available, termed HIV TAT specific factor 1, claimed to be a co-factor required for Tat activation of HIV-1 transcription (gene ID: 401233) We therefore wanted to verify by an independent method that this putative gene is actually transcribed in our patient, and secondly, to determine whether this gene transcript is a constituent of other cell types than blood leucocytes. Figure  1 shows the TaqMan qPCR analysis of mRNA expression of the HTATSF1P2 gene in the patient relative to that of a normal child, verifying that it was up-regulated at all three sampling occasions, as was implicated by the array analyses. Figure 2 shows that the HTATSF1P2 gene is expressed at an approximatively similar level when relative to 18S expression in a variety of tissues, the exception being bone marrow and the HL60R0Á5 cell line, which showed several-fold increased ratios compared to the other tissues.
Characterization of the HTATSF1P2 gene and putative protein. This gene is located on chromosome 6 (6p25Á2) and spans 2173 base pairs (bp). The related refseq RNA model XR_040703Á2 has a length of 1724 bp and a predicted ORF between 1149 and 1664 bp. The predicted polypeptide of 171 amino acids is encoded in 13 frame. The predicted molecular weight of the protein was calculated to 19Á56 kDa and the isoelectric point to 9Á8. Its localization is predicted to be 65Á2% nuclear, 17Á4% cytoplasmic, 8Á7% cytoskeletal, 4Á3% plasma membrane and 4Á3% mitochondrial. Sequence similarity was found between the putative HTATSF1P2 protein and human HIV Tat-specific factor 1 (45%), mouse HIV Tat-specific factor 1 homologue (45%) and Pongo abelii HIV Tat-specific factor 1 (45%); see Fig. 3 .
A number of other genes appeared, in as two or all three samples analysed, both up-and down-regulated (see Table  3 ). Three genes were up-regulated highly in all three samples: CD177, KRT77 (keratine 77) found in skin and eccrine sweat glands and the cancer suppressor gene RAP1 GTPase activating protein (RAP1GAP). Additionally, three genes were up-regulated highly in two of the three samples; HPR (haptoglobin-related protein) that binds to haemoglobin as efficiently as haptoglobin, the interferon (IFN)-a-inducible protein (IFI27) and SLC2A1, a protein that transports glucose over the blood-brain barrier. Three genes were highly down-regulated in samples one and two: TUBB2A, that encodes the tubulin beta 2A molecule, a control component in the complement cascade (classical pathway), C4BPA (also in the classical pathway) and GNLY located in the cytotoxic granules of T cells.
Deductive strategy
The JAK/signal transducer and activators of transcription (JAK/STAT) pathway. The most highly up-regulated gene in our patient was CD177, a neutrophilic granulocyte membrane protein linked to the JAK2/STAT pathway and characteristically highly up-regulated in chronic myeloproliferative disease, especially in polycythaemia vera (PV) and essential thrombocythaemia (ET) [12] . The aetiology of PV and ET is usually a gain-of-function mutation in the JAK2 Treatment 1  3500  210  102  16  9  Treatment 2  1300  120  45  13  9  Treatment 3  1750  940  80  42  10 Calprotectin and zinc were measured before and after the aphaeresis treatment. There are only two days between treatments 1 and 2.
Whole genome microarray of a patient with Hc & Hz gene, causing increased proliferation of haematopoietic stem cells and over-expression of CD177 and other myeloid cell proteins [13] . However, our patient was not a carrier of the canonic JAK2 mutation V617F. It will be remembered that our patient has a chronic thrombocythosis, with platelet counts exceeding 1000 3 10 9 /l most of the time without, however, showing any other typical signs of PV (Table  1) . Bone marrow showed no signs of ET or other malignancy. The DNA-sequencing (see Methods) of PSTPIP1 did not reveal any mutations within the coding regions, the flanking exon-intron boundaries or the analysed region of the 5' UTR (including the (CCTG) in repeat) of the PSTPIP1 gene. The patient was a heterozygous carrier of three mutations in the MEFV gene, p.E148V, p.I692del, p.V726A.
Along with the CD177 over-expression, JAK2, JAK3, STAT5B, mothers against DPP homologue (Drosophila) (SMAD), suppressor of cytokine signalling (SOCS3), interleukin (IL-18R1), tumour necrosis factor (TNF)-AIP3 interacting protein 1 (TNIP1) and JunB proto-oncogene (JUNB) were also up-regulated in one or two of the three samples. Oncostatin M (OSM) was over-expressed consistently in all three samples obtained from the patient during the study period (Table 4) . STAT3, STAT4, STAT5A, STAT5B, STAT6, SMAD2, SMAD3, SMAD4, SMAD5, SMAD7, SOCS7, MPL proto-oncogene (MPL), GATA binding protein 3 (GATA3) and Fas cell surface death receptor (FAS) were down-regulated in one or two of the three samples. STAT3 (in an alternative probe set) and ubiquitin conjugating enzyme E2 Z (UBE2Z) were down-regulated in all three samples.
Selected gene expressions in other pathways that could, theoretical, be associated with signs and symptoms of the patient are shown in Table 5 .
In view of the extreme hypercalprotectinaemia of our patient we looked for expression of calprotectin, a heterodimer coded for by two genes termed S100A8 and S100A9, respectively, and found it to be moderately up-regulated (1Á7-2Á8-fold for different probes of the S100A8 moiety and 2Á6-4Á6-fold for the S100A9 moiety; see Table 5 ). Another member of the gene family of S100 proteins, S100A12, was up-regulated 7Á5-21-fold.
In view of the pronounced hyperzincaemia of our patient we searched for differentially regulated zinccontaining factors. The majority of zinc-related genes were down-regulated at all three time-points sampled (between 70 and 232 genes; not shown). The up-regulated genes were mainly various zinc finger proteins, whose upregulation rarely exceeded a fold change of 2, except JAZF1 (FC 5 1Á9-5Á7), as well as a few zinc transporter genes, notably SLC30A1 (Table 6 ).
In view of the pronounced thrombocytosis of the patient, we looked into the expression of thrombopoietin (THPO) and its receptor (MPL). There was no gene expression signal for THPO, either in the patient or in the healthy control child (three different probe sets). For MPL, two of three probe sets also failed to detect any signals; the third probe detected lower MPL levels in one of the patient's samples (no. 1) than in one control child, and higher levels in the other one (no. 3); see Table 6 .
A number of genes involved in classical autoinflammatory disorders [14] were found to be not significantly different in the patient and the control children. Pyrin (MEFV) mRNA showed no detectable levels in the patient or in the healthy control children; as for the other members of this family of genes (NLRP1, NLRP12, PYHIN1, etc.), a down-regulation was found in samples 2 and 3; see Table 5 . Similarly, there was no evidence of increased expression of immunoglobulin (Ig)D heavy chains or, indeed, of any other immunoglobulin class or light chains (data not shown). Conversely, caspase-1 (CASP1), a protease that activates the inactive precursor of IL-1, was up-regulated slightly in samples 1 and 2 from the patient.
IL-1 and its receptors (IL1A, IL1B, IL1R1) were found to be up-regulated moderately but, interestingly, the antagonistic factors, IL1RN and the 'decoy' receptor IL1R2, were also up-regulated; IL1R2 was particularly up-regulated more forcefully in the 14 month-sample: more than 10-fold. The IL-6 immunoregulatory system (IL6, IL6RA, IL6ST) was not changed consistently except in the third sample, where the IL6R and IL6ST genes were downregulated moderately (FC 5 1Á7 to 23Á0)
We also looked for the expression patterns of WBC colony-stimulating factors and the corresponding receptors (CSF1, CSF2, CSF3, IL3, IL5, CSF2RA, CSF2RB, CSF3R). None of these were up-or down-regulated significantly in the patient (data not shown).
Metallopeptidases MMP8 and MMP9 were up-regulated (between 2Á4-and 26-fold in different samples), as was ADAM9 (8Á0-10Á6-fold). MMP9 participates in IL-8-dependent mobilization of leucocytes from the bone marrow. ADAM9 encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. It is a membrane-anchored protein which has been implicated in a variety of biological process, involving cell-cell interactions, cell-matrix interactions, fertilization, muscle development and neurogenesis. Metallopeptidase 25 (MMP25) was up-regulated to a lesser extent (1Á3-2Á3-fold), as was the metalloproteinase inhibitor-1 (TIMP1, 1Á5-2Á5-fold). Among the classical acute-phase reactant proteins, consistently strong up-regulation in peripheral PWBC was noted for the orosomucoid-1 gene (ORM1, FC 5 5Á6-9Á8) but not for CRP or haptoglobin.
Discussion
Our patient had the Hc/Hz syndrome as defined clinically and by serum analyses, not familial Mediterranean fever (FMF) or PV/ET, and did not harbour any mutations in the PSTPIP1 or JAK2 genes, but only a compound heterozygosity for MEFV mutations. Compared to previously known cases, this patient displays symptoms not typical for Hc/Hz or FMF [15] . Overall, the severity of symptoms in this case seems to be more pronounced. There is a lack of joint involvement, splenomegaly, hepatomegaly and skin inflammation. The chronic diarrhoea and chronic fever are also atypical, and there is no report of death in previous cases. The weakness and failure to thrive is consistent with Hc/Hz, but we found no evidence of retardation. We hypothesized that by the use of a high-quality wholegenome mRNA expression array we would be able to identify plausible mechanisms behind the signs and symptoms that our patient displayed.
1. The hypercalprotectinaemia is explained plausibly by an up-regulation of the calprotectin complex genes (S100A8, S100A9, but also S100A12), and the serum hyperzincaemia is most probably simply a reflection of the increase in this zinc-transporting protein, as we found previously that tissue zinc levels (hair, nails) are not increased in this patient [8] . As there was no mutation in the calprotectin-raising gene PSTPIP1, the mechanism for the Hc/Hz-like biomarker changes must lie elsewhere. 2. The thrombocytosis reflects a general up-regulation of the JAK/STAT pathway; for instance, by oncostatin (OSM), IL18R1 and SOCS3. This links our patient's persistent thrombocytosis with essential thrombocythaemia, a neoplastic disease, but also to conditions with anaemia/tissue hypoxia inducing higher erythropoetin levels, in turn causing reactive thrombocytosis by JAK/ STAT signalling. Signs of a neoplastic origin of our patient's disease are lacking in bone marrow smears. The classical mutation JAK2 V617F, seen in PV and a proportion of ET patients, was absent. 3. The febrile state probably reflects up-regulation of interleukin genes, their activators such as caspase, CIP29 and the interleukin receptors. Notably, IL-6 was not part of the pattern. There were no signals from the probe sets for the MEFV gene either in the patient or in the control children, thus the pyrin expression data is inconclusive.
Other genes known to be involved in autoinflammatory disorders proved to be negative. These data confirm our previous conclusion [6, 8] that this patient has a unique set of characteristics different from the previously defined autoinflammatory syndromes, even in the most recent literature [16] . 4. The presenting signs that brought the patient to hospital in the first place were the intestinal symptoms; these 
Genes up-and down-regulated in the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway; the negative sign (-) indicates down-regulation. Samples were taken at three different time points, 9 months, 14 months and 17 months. Results reported as fold change (FC) compared to a healthy age-and sexmatched control. All FC-values have a change P-value < 0Á05; nc 5 no change; SMAD 5 SMAD, mothers against DPP homologue 4 (Drosophila); SOCS 5 suppressor of cytokine signalling; NFkB1 5 nuclear factor kappa B1; MPL 5 MPL proto-oncogene, thrombopoietin receptor; GATA3 5 GATA binding protein 3; IL-18 5 interleukin 18; UBE2Z 5 ubiquitin conjugating enzyme E2 Z; TNIP1 5 TNFAIP3 interacting protein 1; FAS 5 Fas cell surface death receptor; JUNB 5 JunB proto-oncogene, AP-1 transcription factor subunit; OSM 5 oncostatin M. [7, 17] . Gene expressions up-and down-regulated in the pathways classical autoinflammatory disorders. The negative sign (-) indicates down-regulation; nc 5 no change; gene expression level is the same in sample as in healthy control. Results reported as fold change (FC) compared to a healthy age-and sex-matched control. All FC-values have a change P-value < 0Á05. CAPS 5 cryopyrin-associated periodic syndromes; FCAS 5 familial cold autoinflammatory syndrome; MWS 5 Muckle-Wells syndrome; CINCA/NOMID 5 chronic infantile neurological cutaneous articular syndrome/neonatal-onset multi-systemic inflammatory disease; Ig 5 immunoglobulin; PSTPIP1 5 proline-serine-threonine phosphatase-interacting protein 1. could be due to up-regulation of the high mobility group box 1 (HMBG1) gene seen in the first sample. HMBG1 signalling initiates a proinflammatory response in several sites such as the brain, producing fever and anorexia, and the intestines, causing loss of epithelial barrier function.
One of the major up-regulated probe sets was annotated recently to a pseudogene called HTATSF1P2. The putative protein that would be coded from this gene appears to be quite different from the few sister genes, although major shared structural elements are also evident. The existence of the protein has not yet been addressed, but the presence of mRNA for this gene in all tested cell lines in about equal amounts point to a possible role of a housekeeping type (Fig. 3) . Such a functional role may not be dependent upon actual synthesis of the protein: recently, pseudogene mRNA has been suggested to be active as regulators of cellular function through competition with mRNA transcribed from the corresponding real genes [17] . As the predicted role of the HTATSF1 gene itself is T cell regulation, we should not rule out that up-regulation of the HTATSF1P2 pseudogene contributes to the symptoms and signs of our patient. Further studies of this gene system are warranted.
The major limitation to this work is that we have had only one patient to study, now deceased. We hope that Expression of genes that define well-known mechanistic pathways in the inflammatory response. Samples were taken at three different timepoints: 9 months, 14 months and 17 months. Results reported as fold change (FC) compared to a healthy age-and sex-matched control. No change between patients and healthy controls reported as nc. All FC-values have a change P-value < 0Á05. additional patients will be found and studied in the future, and we suggest strongly that such studies should include whole-genome expression array data.
By the use of a global gene expression array we have been able to find plausible mechanisms behind a number of signs and symptoms that this atypical Hc/Hz patient displayed. While we failed on this occasion in devising a novel mode of treatment that could have saved the patient, we think that the findings demonstrate that it is a viable option to introduce gene expression arrays more actively in clinical diagnostic work-up of difficult/challenging cases in the hope of identifying pathogenic mechanisms and devising individualized therapeutic strategies.
